HK1166331A1 - 抗- 抗體用於治療腦病的應用 - Google Patents

抗- 抗體用於治療腦病的應用

Info

Publication number
HK1166331A1
HK1166331A1 HK12107020.5A HK12107020A HK1166331A1 HK 1166331 A1 HK1166331 A1 HK 1166331A1 HK 12107020 A HK12107020 A HK 12107020A HK 1166331 A1 HK1166331 A1 HK 1166331A1
Authority
HK
Hong Kong
Prior art keywords
tau
antibody
treatment
brain diseases
brain
Prior art date
Application number
HK12107020.5A
Other languages
English (en)
Inventor
貝恩德．博爾曼
烏爾裡希．格普費特
菲奧娜．格呂寧格爾
瓦爾特．胡貝爾
漢斯-威利．克雷爾
瓦萊裡婭．利夫可
奧拉夫．蒙迪戈爾
索尼亞．奧夫納
勞倫斯．奧茲曼
邁克爾．施雷爾姆
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1166331A1 publication Critical patent/HK1166331A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
HK12107020.5A 2009-06-10 2012-07-18 抗- 抗體用於治療腦病的應用 HK1166331A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09007656 2009-06-10
EP09008487 2009-06-30
PCT/EP2010/003437 WO2010142423A2 (en) 2009-06-10 2010-06-08 Use of an anti-tau ps422 antibody for the treatment of brain diseases

Publications (1)

Publication Number Publication Date
HK1166331A1 true HK1166331A1 (zh) 2012-10-26

Family

ID=42753372

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12107020.5A HK1166331A1 (zh) 2009-06-10 2012-07-18 抗- 抗體用於治療腦病的應用

Country Status (23)

Country Link
US (2) US8609097B2 (zh)
EP (1) EP2440578B1 (zh)
JP (2) JP2012529275A (zh)
KR (1) KR101429367B1 (zh)
CN (1) CN102459333B (zh)
AR (1) AR077016A1 (zh)
AU (1) AU2010257799B2 (zh)
BR (1) BRPI1012993A2 (zh)
CA (1) CA2762594C (zh)
CL (1) CL2011003122A1 (zh)
CO (1) CO6450613A2 (zh)
CR (1) CR20110606A (zh)
EC (1) ECSP11011514A (zh)
HK (1) HK1166331A1 (zh)
IL (1) IL216509A0 (zh)
MA (1) MA33339B1 (zh)
MX (1) MX2011012837A (zh)
NZ (1) NZ596187A (zh)
PE (1) PE20120543A1 (zh)
RU (1) RU2536247C2 (zh)
SG (1) SG176754A1 (zh)
TW (1) TW201103560A (zh)
WO (1) WO2010142423A2 (zh)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
LT3345903T (lt) 2009-06-10 2019-12-10 Chugai Pharmaceutical Co Ltd Tetracikliniai junginiai
RU2573392C3 (ru) 2010-08-20 2021-06-24 Чугаи Сейяку Кабусики Кайся Композиция, содержащая тетрациклические соединения
JP2014503178A (ja) 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗タウ抗体
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
PT2758433T (pt) 2011-09-19 2018-01-19 Axon Neuroscience Se Terapia à base de proteínas e diagnóstico de patologia mediada por tau na doença de alzheimer
CA3234629A1 (en) 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
EP2794652B1 (en) 2011-12-21 2017-11-15 F. Hoffmann-La Roche AG Rapid method for cloning and expression of cognate antibody variable region gene segments
AU2013268364B2 (en) 2012-05-31 2018-02-08 Osaka City University Therapeutic agent or prophylactic agent for dementia
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
JP5759568B2 (ja) 2012-09-25 2015-08-05 中外製薬株式会社 Ｒｅｔ阻害剤
WO2014096321A1 (en) * 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
LT2935326T (lt) * 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
BR112016013562A2 (pt) * 2013-12-20 2017-10-03 Hoffmann La Roche Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
KR20160142383A (ko) 2014-04-25 2016-12-12 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
KR102478887B1 (ko) 2014-04-25 2022-12-16 추가이 세이야쿠 가부시키가이샤 4환성 화합물을 고용량 함유하는 제제
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
CN107074938A (zh) * 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
RS61431B1 (sr) * 2014-11-19 2021-03-31 Axon Neuroscience Se Humanizovana antitela na tau u alchajmerovoj bolesti
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CA2973857C (en) 2015-01-16 2023-11-07 Chugai Seiyaku Kabushiki Kaisha Combination drug
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
KR102648281B1 (ko) 2015-04-16 2024-03-14 하. 룬드벡 아크티에셀스카브 항-pacap 항체 및 그의 용도
RU2732122C2 (ru) 2015-06-05 2020-09-11 Дженентек, Инк. Антитела против тау-белка и способы их применения
US9862763B2 (en) * 2015-06-24 2018-01-09 Hoffmann-La Roche Inc. Humanized anti-tau(pS422) antibodies and methods of use
TN2017000543A1 (en) * 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
CA2991451A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
PT3334761T (pt) * 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
TWI770020B (zh) 2016-04-15 2022-07-11 丹麥商Ｈ朗德貝克公司 人類化抗pacap 抗體及其用途
MY197836A (en) 2016-07-12 2023-07-20 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
MX2019006334A (es) 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
MX2019009817A (es) 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2019077500A1 (en) 2017-10-16 2019-04-25 Eisai R&D Management Co., Ltd. ANTI-WATER ANTIBODIES AND USES THEREOF
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
WO2019149798A1 (en) * 2018-02-01 2019-08-08 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
PE20210346A1 (es) 2018-07-03 2021-02-25 Hoffmann La Roche Oligonucleotidos para modular la expresion de tau
EP3829634A1 (en) 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy
AR116113A1 (es) 2018-09-04 2021-03-31 Chugai Pharmaceutical Co Ltd Método para fabricar un compuesto tetracíclico
IL299292A (en) 2020-06-25 2023-02-01 Merck Sharp & Dohme Llc High-affinity antibodies to tau phosphorylated at serine 413
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JPH07507044A (ja) 1991-12-06 1995-08-03 マックス−プランク−ゲゼルシャフト　ツール　フェルデルング　デル　ヴィッセンシャフテン　エー．ヴェー． アルツハイマー病の診断および治療用の新規な手段
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
IT1312107B1 (it) * 1999-05-14 2002-04-04 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
EP1876185A1 (en) 2006-07-04 2008-01-09 F. Hoffmann-La Roche Ag An antibody which recognizes phosphorylated polypeptides

Also Published As

Publication number Publication date
EP2440578B1 (en) 2017-03-08
CR20110606A (es) 2012-01-12
MX2011012837A (es) 2011-12-16
ECSP11011514A (es) 2012-01-31
RU2011152816A (ru) 2013-07-20
CO6450613A2 (es) 2012-05-31
US20130310541A1 (en) 2013-11-21
KR20120024952A (ko) 2012-03-14
BRPI1012993A2 (pt) 2018-01-16
MA33339B1 (fr) 2012-06-01
SG176754A1 (en) 2012-01-30
US20110059093A1 (en) 2011-03-10
WO2010142423A3 (en) 2011-05-26
AU2010257799A1 (en) 2011-12-01
JP6513617B2 (ja) 2019-05-15
AR077016A1 (es) 2011-07-27
IL216509A0 (en) 2012-02-29
JP2017031176A (ja) 2017-02-09
RU2536247C2 (ru) 2014-12-20
PE20120543A1 (es) 2012-05-23
CN102459333B (zh) 2015-07-15
CL2011003122A1 (es) 2012-07-20
CA2762594A1 (en) 2010-12-16
US9290567B2 (en) 2016-03-22
KR101429367B1 (ko) 2014-08-11
TW201103560A (en) 2011-02-01
US8609097B2 (en) 2013-12-17
EP2440578A2 (en) 2012-04-18
CA2762594C (en) 2017-02-28
NZ596187A (en) 2013-11-29
CN102459333A (zh) 2012-05-16
JP2012529275A (ja) 2012-11-22
AU2010257799B2 (en) 2013-10-17
WO2010142423A2 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
HK1166331A1 (zh) 抗- 抗體用於治療腦病的應用
HRP20181320T1 (hr) Ljudska anti-tau protutijela
IL221517A (en) A device for treating headaches
IL253293A0 (en) Desferrioxamine complexes of metals for the treatment of diseases related to the immune system
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
EP2410855A4 (en) PROCESS FOR THE PREPARATION OF ALOGLIPTIN
ZA201202504B (en) Process for the preparation of calcobutrol
HK1165813A1 (zh) 用於治療 的抗 抗體
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
PL390042A1 (pl) Sposób wytwarzania kwasu chlebowego
EP2544686A4 (en) COMBINED METHODS FOR THE TREATMENT OF DISEASES
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
PL388931A1 (pl) Sposób otrzymywania fluorokarbofunkcyjnych silseskwioksanów
EP2536436A4 (en) ANTIMIR-451 FOR THE TREATMENT OF POLYCYTHEMICS
ZA201302639B (en) Antibodies for the treatment of hiv
PT2593423E (pt) Processo para a preparação de agentes de contraste
IL218160A0 (en) Desferrioxamine-metal complexes for the treatment of immune-related disorders
IL215143A0 (en) Process for the preparation of alogliptin
IL220160A (en) A process for the preparation of defrasirox
GB0920651D0 (en) Molecular methods for the treatment of disease
PL389568A1 (pl) Sposób otrzymywania 2-metyloglicydolu
HUP0900258A2 (en) The treatment of brain tumours by pyrithiamine
AU2009902409A0 (en) Method for the treatment of mental disorders
AU2009900341A0 (en) Method for the treatment of mental disorders